Measurement of oxidation in plasma Lp(a) in CAPD patients using a novel ELISA

Kidney International

Volumn 54, Issue 2, 1998, Pages 637-645

  Podrez, Eugene A ^b   O'Neil, June ^b   Salomon, Robert G ^b   Schreiber, Martin J ^b   Hoff, Henry F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Atherosclerosis; Coronary artery disease; LGE2; Lipoproteins; Oxidative stress; Phospholipid endoperoxide; Protein adducts

Indexed keywords

ALDEHYDE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; EPITOPE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; POLYCLONAL ANTIBODY; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY FAILURE; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL;

EID: 0031870436     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00034.x     Document Type: Article

References (52)

1. FILLIT H, ELION E, SULLIVAN J, SHERMAN R, ZABRISKIE JB: Thiobarbituric acid reactive material in uremic blood. Nephron 29:40-43, 1981
2. RICHARD MJ, ARNAUD J, JURKOVITZ C, HACHACHE T, MEFTAHI H, LAPORTE F, FORET M, FAVIER A, CORDONNIER D: Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 57:10-15, 1991
3. TOBOREK M, WASIK T, DROZDZ M, KLIN M, MAGNER-WROBEL K, KOPIECZNA-GRZEBIENIAK E: Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 41:1229-1232, 1992
4. RITZ E, AUGUSTIN J, BOMMER J, GNASSO A, HABERBOSH W: Should hyperlipidemia of renal failure be treated? Kidney Int 28(Suppl 17):84-87, 1985
5. REGNSTRÖM J, NILSSON J, TORNVALL P, LANDOU C, HAMSTEN A: Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339:1183-1186, 1992
6. WITZTUM JL, STEINBERG D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785-1792, 1991
7. STRINGER MD, GÖRÖG PG, FREEMAN A, KAKKAR VV: Lipid peroxides and atherosclerosis. Brit Med J 298:281-283, 1989
8. CAZZOLATO G, AVOGARO P, BITTOLO-BON G: Characterization of a more electronegatively charged LDL subfraction by ion exchange HPLC. Free Rad Biol Med 11:247-253, 1991
9. BELLAZZI R, MAGGI E, BELLOMO G, FINARDI G, GAZO A, NAI M, ROMANINI D, FALASHI F, FRATTONI A, PERANI G: Low-density lipoprotein oxidation and anti oxidized LDL antibodies in peritoneal dialysis patients. Adv Perit Dial 9:312-317, 1993
10. SALONEN JT, YLÄ-HERTTUALA S, YAMAMOTO R, BUTLER S, KORPELA H, SALONEN R, NYYSSÖNEN K, PALINSKI W, WITZTUM JL: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 339:883-887, 1992
11. HOLVOET P, PEREZ G, ZHAO Z, BROUWERS E, BERNAR H, COLLEN D: Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 95:2611-2619, 1995
12. KOTANI K, MAEKAWA M, KANNO T, KONDO A, TODA N, MANABE M: Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1215:121-125, 1994
13. SALMON S, MAZIERE C, THERON L, BEUCLER I, JARRIER-AYRAULT M, GOLDSTEIN S, POLONOVSKI J: Immunologial detection of low-density lipoproteins modified by malondialdehyde in vitro or in vivo. Biochim Biophys Acta 920:215-220, 1987
14. ITABE H, YAMAMOTO H, IMANAKA T, SHIMAMURA K, UCHIYAMA H, KIMURA J, SANAKA T, HATA Y, TAKANO T: Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 37:45-53, 1996
15. MAGGI E, BELLAZZI R, FALASCHI F, FRATTONI A, PERANI G, FINARDI G, GAZO A, NAI M, ROMANINI D, BELLOMO G: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 45:876-883, 1994
16. APANAY DC, NEYLAN JF, RAGAB MS, SGOUTAS DS: Cyclosporin increases the oxidizability of low-density-lipoproteins in renal transplant recepients. Transplantation 58:663-669, 1994
17. WESTHUYZEN J, SALTISSI D, HEALY H: Oxidation of low density lipoprotein in hemodialysis patients: Effect of dialysis and comparison with matched controls. Atherosclerosis 129:199-205, 1997
18. SERDYUK PS, MORION RE: Resistance of lipoproteins from continuous ambulatory peritoneal dialysis patients to in vitro oxidation. Metabolism 46:833-839, 1997
19. KLEINVELD HA, DUIF PFCCM, PEKELHARING, HLM, VAN RUN HJM: Oxidation of lipoprotein(a) and low density lipoprotein containing density gradient ultracentrifugation fractions. Biochim Biophys Acta 1303:15-21, 1996
20. JÜRGENS G, ASHY A, ESTERBAUER H: Detection of new epitopes formed upon oxidation of low-density lipoprotein, lipoprotein (a) and very-low-density lipoprotein. Use of an antiserum against 4-hydroxynonenal-modified low-density lipoprotein. Biochem J 265:605-608, 1990
21. NARUSZEWICZ M, SELINGER E, DAVIGNON J: Oxidative modification of lipoprotein(a) and the effect of β-carotene. Metabolism 41:1215-1224, 1992
22. SATTLER W, KOSTNER GM, WAEG G, ESTERBAUER H: Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins. Biochim Biophys Acta 1081:65-74, 1991
23. MCCONNELL AM, GIESEG SP, STANLEY KK: Hypoehlorite oxidation causes cross-linking of Lp(a). Biochim Biophys Acta 1225:180-186, 1994
24. ESTERBAUER H, GEBICKI J, PUHL H, JURGENS G: The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13:341-390, 1992
25. MORROW JD, HARRIS TM, ROBERTS II LJ: Noncyclooxgenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids. Anal Biochem 184:1-10, 1990
26. 2 and a novel intramolecular 1,2-hydride shift during endoperoxide fragmentation in aqueous solution. J Am Chem Soc 106:6049-6060, 1984
27. 2 with proteins. J Org Chem 59:6038-6043, 1994
28. 2 with proteins. Chem Res Toxicol 8:61-67, 1995
29. SALOMON RG, SUBBANAGOUNDER G, SINGH U, O'NEIL J, HOFF HF: Oxidation of low-density lipoproteins produces levuglandin-protein adducts. Chem Res Toxicol 10:750-759, 1997
30. 2, an oxidation product of arachidonic acid. Biochim Biophys Acta 1344:1-5, 1997
31. HATCH FT, LEES RS: Practical method for plasma lipoprotein analysis. Adv Lipid Res 6:2-63, 1968
32. PEPIN JM, O'NEIL JA, HOFF HF: Quantification of apo (a) and apoB in human atherosclerotic lesions. J Lipid Res 32:317-327, 1991
33. REDGRAVE TG, ROBERTS DCK, WEST CE: Separation of lipoproteins by density-gradient ultracentrifugation. Anal Biochem 65:42-49, 1975
34. 2 with proteins. Prostaglandins 34:643-656, 1987
35. 2. J Org Chem 55:3164-3175, 1990
36. SMITH PK, KROHN RI, HERMANSON GT, MALLIA AK, GARTNER FH, PROVENZANO MD, FUJIMOTO EK, GOEKE NM, OLSON BJ, KLENK DC: Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85, 1985
37. HARLOW E, LANE L: Antibodies. Cold Spring Harbor Laboratory, Cold Spring Harbor, 1988
38. 2-protein adducts in human plasma and vasculature. Chem Res Toxicol 10:536-535, 1997
39. FLESS GM, SNYDER ML, SCANU AM: Enzyme-linked immunoassay for Lp(a). J Lipid Res 30:651-662, 1989
40. TIJSSEN P: Practice and Theory of Enzyme Immunoassays (Laboratory Techniques in Biochemistry and Molecular Biology, v.15). Elsevier, Amsterdam, 1985
41. MOOSER V, MARCOVINA SM, WHITE AL, HOBBS HH: Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 98:2414-2424, 1996
42. TRENKWALDER E, GRUBER A, KÖNIG P, DIEPLINGER H, KRONENBERG F: Increased plasma concentrations of LDL-unbound apo (a) in patients with end-stage renal desease. Kidney Int 52:1685-1692, 1997
43. VAN BERKEL TJC, DE RIJKE YB, KRUIJT JK: Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells J Biol Chem 266:2282-2289, 1991
44. RAGAB MS, SELVARAJ P, SGOUTAS DS: Oxidized lipoprotein (a) induces cell adhesion molecule Mac-1 (CD 11b) and enhances adhesion of the monocytic cell line U937 to cultured endothelial cells. Atherosclerosis 123:103-113, 1996
45. KNIGHT BL, PEROMBELON YFN, SOUTAR AK, WADE DP, SEED M: Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects. Atherosclerosis 87:227-237, 1991
46. REN S, MAN RYK, ANGEL A, SHEN GX: Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells. Atherosclerosis 128:1-10, 1997
47. CHESSMAN MD, HEYKA RJ, PAGANINI MP, O'NEIL J, SKIBINSKI CI, HOFF HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
48. AVRAM MM, SREEDHARA R, PATEL N, CHATOPADHYAY J, THU T, FEIN P: Is an elevated level of serum lipoprotein (a) a risk factor for cardiovascular disease in CAPD patients? Adv Perit Dial 12:266-271, 1996
49. BERLINER JA, NAVAB M, FOGELMAN AM, FRANK JS, DEMER LL, EDWARDS PA, WATSON AD, LUSIS AJ: Atherosclerosis: Basic mechanisms: Oxidation, inflammation, and genetics. Circulation 91:2488-2496, 1995
50. GALLE J, STUNZ P, SCHOLLMEYER P, WANNER C: Oxidized LDL and lipoprotein(a) stimulate renin release of juxtaglomerular cells. Kidney Int 47:45-52, 1995
51. HAJJAR KA, NACHMAN RL: The role of lipoprotein(a) in atherogenesis and thrombosis. Annu Rev Med 47:423-442, 1996
52. WANNER C, GREIBER S, KRAMER-GUTH A, HEINLOTH A, GALLLE J: Lipids and progression of renal disease: Role of modified low density lipoprotein and lipoprotein(a). Kidney Int 52:5102-S106, 1997